The role of insulin-like growth factor I monitoring in growth hormone-treated children.
Growth hormone (GH) therapy has evolved rapidly over the past decade, and continuing research has established a clear role for therapeutic GH in a wide spectrum of disorders, including idiopathic GH deficiency (childhood- and adult-onset), Turner syndrome, Prader-Willi syndrome, small-for-gestational age children with failure of catch-up growth, AIDS-related catabolism, children with chronic renal failure, and idiopathic short stature. Although GH is used therapeutically in a wide variety of conditions, actual guidelines regarding the logistics of GH dosing continue to evolve, with data emerging regarding efficacy and safety. This review proposes a role for insulin-like growth factor I measurement in optimizing GH dosing.
Park
Patricia
P
Division of Endocrinology, Department of Pediatrics, Mattel Children's Hospital at UCLA, Los Angeles, CA 90095-1752, USA.
Cohen
Pinchas
P
D000172:Acromegaly / Q000175:diagnosis; D000328:Adult; D000367:Age Factors; D002648:Child; D016903:Drug Monitoring; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D009369:Neoplasms / Q000209:etiology; D012306:Risk; D012737:Sex Factors
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I